Levothyroxine is a l-thyroxine sold in the U.S. under 11 brand and generic names, for goiter, myxedema and thyroid neoplasms. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Euthyrox (application NDA021292). Other levothyroxine products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Administer once daily, on an empty stomach, one-half to one hour before breakfast. ( 2.1 ) Administer at least 4 hours before or after drugs that are known to interfere with absorption. ( 2.1 ) Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption. ( 2.1 ) Starting dose depends on a variety of factors, including age, body weight, cardiovascular status, concomitant medical conditions (including pregnancy), concomitant medications, co-administered food, and the specific nature of the condition being treated. Peak therapeutic effect may not be attained for 4 to 6 weeks. ( 2.2 ) See full prescribing information for dosing in specific patient populations. ( 2.3 ) Adequacy of therapy determined with periodic monitoring of TSH and/or T4 as well as clinical status. ( 2.4 ) 2.1 General Administration Information Administer EUTHYROX tablets orally as a single daily dose, on an empty stomach, one-half to one hour before breakfast. Administer EUTHYROX at least 4 hours before or after drugs known to interfere with EUTHYROX absorption [see Drug Interactions (7.1) ]. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect EUTHYROX absorption [see Drug Interactions (7.9) , Clinical Pharmacology (12.3) ]. Administer EUTHYROX to infants and children who cannot…
associated with EUTHYROX therapy are primarily those of hyperthyroidism due to therapeutic overdosage [see Warnings and Precautions (5) , Overdosage (10) ]. They include the following: General: fatigue, increased appetite, weight loss, heat intolerance, fever, excessive sweating Central Nervous System: headache, hyperactivity, nervousness, anxiety, irritability, emotional lability, insomnia Musculoskeletal: tremors, muscular weakness and cramps Cardiovascular: palpitations, tachycardia, arrhythmias, increased pulse and blood pressure, heart failure, angina, myocardial infarction, cardiac arrest Respiratory: dyspnea Gastrointestinal: diarrhea, vomiting, abdominal cramps and elevations in liver function tests Dermatologic: hair loss, flushing, rash Endocrine: decreased bone mineral density Reproductive: menstrual irregularities, impaired fertility Seizures have been reported rarely with levothyroxine therapy. Adverse reactions associated with EUTHYROX are primarily those of hyperthyroidism due to therapeutic overdosage: arrhythmias, myocardial infarction, dyspnea, muscle spasm, headache, nervousness, irritability, insomnia, tremors, muscle weakness, increased appetite, weight loss, diarrhea, heat intolerance, menstrual irregularities, and skin rash. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Provell Pharmaceuticals, LLC at 1-888-899-7041 or FDA…
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 70/100 | Prescription | Tablet | Generic | $2 | View → | |
| 2 |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| 125;GG;337 | — | brown | capsule | — |
| L26 | — | pink | round | — |
| 25;T;4 | 25 ug | orange | capsule | — |
| M;L;4 | 25 ug | orange | oval | — |
| M;L;5 | 50 ug | white | oval | — |
| M;L;6 | 75 ug | purple |
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Levothyroxine Sodium Tablets USP 150 mcg
Subpotent Drug
MACLEODS PHARMA USA, INC · Feb 26, 2026
Levothyroxine Sodium Tablets
Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.
Alvogen, Inc · Dec 31, 2025
Levothyroxine Sodium Tablets
Subpotent: During long term stability testing of Levothyroxine Sodium Tablets USP for 88 mcg, the assay content was observed below the approved specification range.
ACCORD HEALTHCARE, INC. · Sep 16, 2025
Levoxyl (levothyroxine sodium tablets
Subpotent drug
Pfizer · Jul 29, 2025
Levothyroxine Sodium Tablets
Subpotent Drug: Assay below the approved specification
ACCORD HEALTHCARE, INC. · Jun 20, 2025
The elimination half-life of levothyroxine is about 6 to 7 days in adults with normal thyroid function. Half-life varies markedly with thyroid status: roughly 9 to 10 days in hypothyroidism (the condition being treated) and only 3 to 4 days in hyperthyroidism. This is the parent hormone (T4); its active product T3 has a shorter, not longer, half-life, so no longer-lived active metabolite applies.
SYNTHROID (levothyroxine sodium) tablets — DailyMed label ↗Half-life is how long the body takes to clear half a dose. It is not the same as how long a drug test can detect it, and it varies with age, kidney and liver function.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
EUTHYROX is contraindicated in patients with uncorrected adrenal insufficiency [ see Warnings and Precautions (5.3) ]. Uncorrected adrenal insufficiency. ( 4 )
See full prescribing information for drugs that affect thyroid hormone pharmacokinetics and metabolism (e.g., absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to EUTHYROX. ( 7 ) 7.1 Drugs Known to Affect Thyroid Hormone Pharmacokinetics Many drugs can exert effects on thyroid hormone pharmacokinetics (e.g. absorption, synthesis, secretion, catabolism, protein binding, and target tissue response) and may alter the therapeutic response to EUTHYROX (see Tables 2 – 5). Table 2: Drugs That May Decrease T4 Absorption (Hypothyroidism) Potential impact: Concurrent use may reduce the efficacy of EUTHYROX by binding and delaying or preventing absorption, potentially resulting in hypothyroidism Drug or Drug Class Effect Calcium Carbonate Ferrous Sulfate Calcium carbonate may form an insoluble chelate with levothyroxine, and ferrous sulfate likely forms a ferric-thyroxine complex. Administer EUTHYROX at least 4 hours apart from these agents. Orlistat Monitor patients treated concomitantly with orlistat and EUTHYROX for changes in thyroid function. Bile Acid Sequestrants -Colesevelam -Cholestyramine -Colestipol Ion Exchange Resins -Kayexalate -Sevelamer Bile acid sequestrants and ion exchange resins are known to decrease levothyroxine absorption. Administer EUTHYROX at least 4 hours prior to these drugs or…
| 70/100 |
| Prescription |
| Capsule |
| Generic |
| $2 |
| View → |
| 3 | 64/100 | Prescription | Tablet | Generic | $2 | View → |
| 4 | 64/100 | Prescription | Tablet | Generic | $2 | View → |
| 5 | 62/100 | Prescription | Solution | Generic | $2 | View → |
| 6 | 60/100 | Prescription | Solution | Generic | $2 | View → |
| 7 | 56/100 | Prescription | Capsule | Generic | $2 | View → |
| 8 | Not yet rated | Prescription | Tablet | Generic | $2 | View → |
| 9 | Not yet rated | Prescription | Tablet | Generic | $2 | View → |
| 10 | Not yet rated | Prescription | Solution | Generic | $2 | View → |
| oval |
| — |
| M;L;8 | 100 ug | yellow | oval | — |
|---|
| M;L;10 | 125 ug | gray | oval | — |
|---|
| M;L;11 | 150 ug | blue | oval | — |
|---|